Cargando…
Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data
BACKGROUND: Vitiligo-like depigmentation is a common skin adverse event in patients receiving immunotherapy for malignant melanoma, but has been rarely reported in patients with non-melanoma malignancies. To better understand this immune-related adverse event, we reviewed a series of cases of immuno...
Autores principales: | Rao, Hui, Guo, Zheng, Wen, Xuejiao, Zeng, Xiaoli, Wu, Longqiu, Huang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881409/ https://www.ncbi.nlm.nih.gov/pubmed/36713515 http://dx.doi.org/10.3389/fonc.2022.1099108 |
Ejemplares similares
-
Development of Vitiligo-Like Depigmentation after Treatment of Lentigo Maligna Melanoma with 5% Imiquimod Cream
por: Kim, Na Hee, et al.
Publicado: (2018) -
Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011) -
Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report
por: Yun, Sook Jung, et al.
Publicado: (2020) -
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo
por: Agarwal, Priti, et al.
Publicado: (2014) -
CCL22 to activate Treg migration and suppress depigmentation in vitiligo
por: Eby, Jonathan M., et al.
Publicado: (2015)